Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Finalizes Rules For Coordinated Trial Safety Assessment Under CTR

Executive Summary

A new implementing regulation provides a legal basis for EU member states to cooperate on the assessment of trial-related safety reports linked to an active substance instead of the investigational medicinal product. 

You may also be interested in...



The EU’s New Clinical Trial System Is Just Two Weeks Away: Are You Ready?

When the new Clinical Trial Information System goes live at the end of January, it will usher in many practical and operational considerations that sponsors need to be aware of.

EU Explains Safety Reporting Under New Clinical Trial Regs

An updated guidance document on the EU Clinical Trials Regulation has been published, with new information regarding the requirements for reporting safety issues in clinical trials. The European Medicines Agency says progress with developing the new clinical trial information system is going well but some more enhancements are needed.

EU Clinical Trials Delayed By Poor Reference Safety Information

EU regulators are increasingly raising objections over the reference safety information that companies include in their clinical trial applications and updated investigator's brochures.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel